NDATOPICALCREAM
Approved
May 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
DIFFERIN (adapalene) by Galderma is mechanism of action: adapalene acts on retinoid receptors. Approved for acne vulgaris, photoaging, photodamage. First approved in 2000.
Drug data last refreshed 22h ago
Mechanism of Action
Mechanism of Action: Adapalene acts on retinoid receptors. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne…
Pharmacologic Class:
Retinoid
Indications (3)
Worked on DIFFERIN at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.